To the Editor,

Inflammatory eye disease, namely uveitis, is a well-documented adverse effect of immunotherapy, a novel treatment option that has revolutionised the outcomes for patients with metastatic melanoma. By blocking immune checkpoint proteins CTLA-4 (Ipilimumab) and PD-1 (Nivolumab, Pembrolizumab) on the surface of T-lymphocytes, the drugs cause the desired effect of tumour regression [1], but can also result in numerous immune-related adverse effects (irAEs) [2]. The incidence of uveitis secondary to CTLA-4 and PD-1 blockade in melanoma patients is said to be less than 1% [3, 4]. The phenomenon has also been reported in patients treated with BRAF/MEK inhibitor-targeted therapies (Dabrafenib/Trametinib/Vemurafenib) [5].

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD